Lincon elvis morales

Who benefits from intensification with docetaxel? Presentation by Gero Kramer, MD @MedUni_Wien. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/46XQndI @Uroweb

LA GUÍA DEFINITIVA PARA DOMINAR LOS 16 TIEMPOS VERBALES: (Guarda este post 🔖)

Exploring adult circumcision: a step-by-step medical animation

Prognostic tool evaluated for early treatment decisions for metastatic hormone-sensitive #ProstateCancer. @Soum_Roy_RadOnc @RadOncUH joins @neerajaiims @huntsmancancer sharing research on the NADIR prognostic model, which predicts early PSA response in #mHSPC patients receiving ADT plus ARPI. #WatchNow > bit.ly/4qm1VyL

Important randomized data (JCOG1019) suggesting that in carefully selected HG T1 patients with a negative re-TUR, active surveillance may achieve comparable oncologic outcomes to BCG, with less toxicity. Encouraging signal - especially in the era of BCG constraints That said, selection is everything. This is not a broad replacement for BCG, but a potential option for a very defined, well-counseled group under close follow-up. As always in #BladderCancer cancer: biology, quality of resection, and vigilance matter. @IBCG_BladderCA @UrogerliMD @MaxKates @tompowles1 @MRoupret @JoshMeeks @joanfundi @AndreaNecchi

The effect of neoadjuvant chemotherapy on survival outcomes subsequent to radical cystectomy in pathological T0 bladder cancer patients: A multicenter large-scale analysis 🌷doi.org/10.4111/icu.20… Investig Clin Urol. 2025;66(5). Jong Ho Park #Cystectomy #NeoadjuvantTherapy

Intermediate-risk prostate cancer isn’t one disease. 🔴 PSMA lights up aggressive biology. 🟢 RM2 lights up favorable biology. Dual-tracer PET may redefine risk stratification beyond PSA + Gleason. #MedTwitter #prostate #Oncology @OncoAlert @OncBrothers @dr_yakupergun @drsarahsam @PTarantinoMD @myESMO @ASCOPost

#VideotecaSCHU: Especialistas de la Universidad de Chile presentaron un caso de nefrectomía radical con trombectomía laparoscópica: un abordaje seguro, mínimamente invasivo y con menor estadía hospitalaria.shorturl.at/SRYQT

🔥@UrolOncol: Feb issue - #BladderCancer! Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience Click here to read the article ▶️ bit.ly/4rPkATV

Neoadjuvant and adjuvant ARPIs in high-risk localized #ProstateCancer. Robert Reiter, MD, @UCLA joins @zklaassen_md @GACancerCenter to discuss why surgery alone isn’t enough (recurrence up to 70%). Phase II data show better pathologic responses with ADT + ARPIs, and phase III trials like PROTEUS and genomic-guided GUNS are underway, plus early signals from neoadjuvant Lu-177 PSMA (LuTectomy). Surgery + systemic therapy may become a new paradigm. #WatchNow > bit.ly/4pAMUbk

Interesting timeline of the last two decades in systemic treatment of muscle invasive bladder cancer.

Use of tranexamic acid with PCNL results in less bleeding and higher stone-free rate @MayoUrology #MayoUroHawaii26

expert reaction to 23 year follow up data from The European Randomized Study of Screening for Prostate Cancer | Science Media Centre sciencemediacentre.org/expert-reactio…

Big stones or tissue slow to pass thru #FANS ? Place basket ADJACENT to fURS? Save ⏰ 1. Don’t need 2 remove laser fiber to use basket 2. Backstop/nudge larger stones along #FANSBasketCombo

@urotoday @TischCancer @UroCancerMD @VUMCurology ctDNA is changing the game for treatment decisions

Cerraste etapas sin aplausos. Te fuiste de lugares donde ya no encajabas. Te alejaste de personas sin hacer ruido. Y ahora, sin darte cuenta, estás siendo impulsado a una versión más grande de ti. Porque soltar no fue el final. Fue el inicio real de tu expansión. Y tu inicio puede comenzar aquí hoy: desarrolloexponencial.net/vsl

Enucleation | Step-by-Step 🐾 Episode: Plane Acquisition 👉 Start at the 5 o’clock position 🕔👇

Next generation stents for #BPH come in an array of comfortable shapes designed to expand the prostatic urethra and alleviate #LUTS without the need for chronic medical therapy in men with bilobar BPH (no median lobe). @proverummedical @zenflowinc @Butterfly_Med @Prodeonmedical #Rivermark #Flostent @SocietyofBPD

🌟Patient-centred Care in CRPC🌟 By @UrsulaVogl #PROSCA25 #GlobalForum25 @OncoAlert @mirrorsmed 🔷 Shared Decision-Making (SDM) 🔹 Cornerstone of patient-centred care 🔹 Integrates patients’ needs, values, and goals 🔹 Ensures treatment decisions reflect what matters most to men with CRPC 🔷 Optimising Therapy in mCRPC 🔹 Focus on sequencing active, life-prolonging treatments 🔹 Keep patients fully informed on efficacy, toxicity, and QoL trade-offs 🔹 Empower men to participate meaningfully in treatment planning 🔷 Communication & Outcomes 🔹 Clear communication of treatment results at the patient level is essential 🔹 Identify opportunities for therapy early and proactively 🔹 Early referral to palliative care improves overall care quality